Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Role of the Immune Environment in Response to Therapy in Breast Cancer

for
Breast Cancer, ER Positive Breast Cancer,
Location: Philadelphia PA
Sponsor: Abramson Cancer Center at Penn Medicine

Sex: Female

Age: 18+

Code: NCT05396612

Recruiting

A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer

for
Metastatic Breast Cancer, Breast Cancer, Breast Cancer Stage IV,
Location: Commack NY, Rockville Centre NY, Harrison NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT06246968

Phase 1, Recruiting

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

for
Advanced Solid Tumors, HNSCC, SCLC, NSCLC,
Location: Boston MA, New York NY, New Haven CT, Miami FL, Toronto,
Sponsor: Tubulis GmbH

Sex: All

Age: 18+

Code: NCT06657222

Phase 1, Phase 2, Recruiting

Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer

for
Anatomic Stage 0 Breast Cancer AJCC v8,
Location: Philadelphia PA
Sponsor: Thomas Jefferson University

Sex: All

Age: 40+

Code: NCT04959474

Recruiting

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

for
Triple Negative Breast Cancer, Breast Cancer
Location: Stanford CA
Sponsor: Stanford University

Sex: All

Age: 18+

Code: NCT04768426

Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

for
Metastatic Breast Cancer, Triple Negative Breast Cancer,
Location: Durham NC, Buffalo NY, Atlanta GA, Lexington KY,
Sponsor: Kathy Miller

Sex: All

Age: 18+

Code: NCT05846789

Phase 2, Recruiting

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

for
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma,
Location: Fairfax VA, Pittsburgh PA, Canton OH, Columbus OH,
Sponsor: OncoNano Medicine, Inc.

Sex: All

Age: 18+

Code: NCT06022029

Phase 1, Recruiting

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

for
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer,
Location: Boston MA, Montreal, Toronto, Jacksonville FL,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18 - 70+

Code: NCT06562192

Phase 1, Recruiting

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

for
Solid Tumor, Adult, Triple Negative Breast Cancer,
Location: Scottsdale AZ, La Jolla CA, Stanford CA
Sponsor: BioEclipse Therapeutics

Sex: All

Age: 18+

Code: NCT04282044

Phase 1, Recruiting

First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

for
Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer,
Location: Baltimore MD
Sponsor: A&G Pharmaceutical Inc.

Sex: All

Age: 18+

Code: NCT05627960

Phase 1, Recruiting

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

for
Breast Cancer, TNBC - Triple-Negative Breast Cancer,
Location: Florham Park NJ, Weston FL, Ann Arbor MI, Cincinnati OH,
Sponsor: Tempus AI

Sex: All

Age: 18 - 70+

Code: NCT07211178

Recruiting

First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.

for
Advanced Triple Negative Breast Cancer,
Location: Vancouver
Sponsor: Nathalie Levasseur

Sex: All

Age: 18+

Code: NCT07299409

Phase 2, Recruiting

Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

for
HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma,
Location: The Bronx NY, Durham NC, San Francisco CA
Sponsor: University of California, San Francisco

Sex: All

Age: 18+

Code: NCT06774027

Recruiting

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

for
Anatomic Stage I Breast Cancer AJCC v8,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT07407920

Phase 2, Recruiting

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

for
HER2 Low Breast Carcinoma, Triple Negative Breast Cancer,
Location: San Francisco CA
Sponsor: Laura Huppert, MD, BA

Sex: All

Age: 18+

Code: NCT06224673

Phase 2, Recruiting

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

for
Breast Cancer, Metastatic Breast Cancer,
Location: New Haven CT, Philadelphia PA, Baltimore MD,
Sponsor: UNC Lineberger Comprehensive Cancer Center

Sex: All

Age: 18+

Code: NCT07340541

Phase 2, Recruiting

Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer

for
Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III,
Location: London
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Sex: All

Age: 18+

Code: NCT07188246

Phase 2, Recruiting

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

for
Anatomic Stage I Breast Cancer AJCC v8,
Location: Atlanta GA
Sponsor: Emory University

Sex: All

Age: 18+

Code: NCT06324240

Phase 1, Recruiting

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

for
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer,
Location: Princeton NJ, Montreal
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07261631

Phase 1, Recruiting

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

for
Cancer, Immunotherapy, Advanced Solid Tumors Cancer,
Location: Frederick MD, St Louis MO, Springfield MO,
Sponsor: Elephas

Sex: All

Age: 18+

Code: NCT07327489

Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial